FDA Prepares For LPAD: Orphan Drug Approvals Are Model
This article was originally published in RPM Report
Executive Summary
One of the bedrock consensus issues throughout the drafting of the “21st Century Cures” legislation has been that the bill should create a pathway for approval of new antibacterials for limited populations – known as LPAD. But what would it actually do?